28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Common activation mechanism of class A GPCRs

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Class A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric process that couples agonist binding to G-protein recruitment, with the hallmark outward movement of transmembrane helix 6 (TM6). However, what leads to TM6 movement and the key residue level changes of this movement remain less well understood. Here, we report a framework to quantify conformational changes. By analyzing the conformational changes in 234 structures from 45 class A GPCRs, we discovered a common GPCR activation pathway comprising of 34 residue pairs and 35 residues. The pathway unifies previous findings into a common activation mechanism and strings together the scattered key motifs such as CWxP, DRY, Na + pocket, NPxxY and PIF, thereby directly linking the bottom of ligand-binding pocket with G-protein coupling region. Site-directed mutagenesis experiments support this proposition and reveal that rational mutations of residues in this pathway can be used to obtain receptors that are constitutively active or inactive. The common activation pathway provides the mechanistic interpretation of constitutively activating, inactivating and disease mutations. As a module responsible for activation, the common pathway allows for decoupling of the evolution of the ligand binding site and G-protein-binding region. Such an architecture might have facilitated GPCRs to emerge as a highly successful family of proteins for signal transduction in nature.

          Related collections

          Most cited references153

          • Record: found
          • Abstract: found
          • Article: not found

          High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

          Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane. We report the crystal structure of a human beta2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resolution. The structure provides a high-resolution view of a human G protein-coupled receptor bound to a diffusible ligand. Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop. Cholesterol, a necessary component for crystallization, mediates an intriguing parallel association of receptor molecules in the crystal lattice. Although the location of carazolol in the beta2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Improved protein-ligand docking using GOLD.

            The Chemscore function was implemented as a scoring function for the protein-ligand docking program GOLD, and its performance compared to the original Goldscore function and two consensus docking protocols, "Goldscore-CS" and "Chemscore-GS," in terms of docking accuracy, prediction of binding affinities, and speed. In the "Goldscore-CS" protocol, dockings produced with the Goldscore function are scored and ranked with the Chemscore function; in the "Chemscore-GS" protocol, dockings produced with the Chemscore function are scored and ranked with the Goldscore function. Comparisons were made for a "clean" set of 224 protein-ligand complexes, and for two subsets of this set, one for which the ligands are "drug-like," the other for which they are "fragment-like." For "drug-like" and "fragment-like" ligands, the docking accuracies obtained with Chemscore and Goldscore functions are similar. For larger ligands, Goldscore gives superior results. Docking with the Chemscore function is up to three times faster than docking with the Goldscore function. Both combined docking protocols give significant improvements in docking accuracy over the use of the Goldscore or Chemscore function alone. "Goldscore-CS" gives success rates of up to 81% (top-ranked GOLD solution within 2.0 A of the experimental binding mode) for the "clean list," but at the cost of long search times. For most virtual screening applications, "Chemscore-GS" seems optimal; search settings that give docking speeds of around 0.25-1.3 min/compound have success rates of about 78% for "drug-like" compounds and 85% for "fragment-like" compounds. In terms of producing binding energy estimates, the Goldscore function appears to perform better than the Chemscore function and the two consensus protocols, particularly for faster search settings. Even at docking speeds of around 1-2 min/compound, the Goldscore function predicts binding energies with a standard deviation of approximately 10.5 kJ/mol. Copyright 2003 Wiley-Liss, Inc.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Crystal structure of the μ-opioid receptor bound to a morphinan antagonist

              Summary Opium is one of the world’s oldest drugs, and its derivatives morphine and codeine are among the most used clinical drugs to relieve severe pain. These prototypical opioids produce analgesia as well as many of their undesirable side effects (sedation, apnea and dependence) by binding to and activating the G-protein-coupled μ-opioid receptor (μOR) in the central nervous system. Here we describe the 2.8 Å crystal structure of the μOR in complex with an irreversible morphinan antagonist. Compared to the buried binding pocket observed in most GPCRs published to date, the morphinan ligand binds deeply within a large solvent-exposed pocket. Of particular interest, the μOR crystallizes as a two-fold symmetric dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6. These high-resolution insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.
                Bookmark

                Author and article information

                Contributors
                Role: Reviewing Editor
                Role: Senior Editor
                Journal
                eLife
                Elife
                eLife
                eLife
                eLife Sciences Publications, Ltd
                2050-084X
                19 December 2019
                2019
                : 8
                : e50279
                Affiliations
                [1 ]deptiHuman Institute ShanghaiTech University ShanghaiChina
                [2 ]deptThe CAS Key Laboratory of Receptor Research Shanghai Institute of Materia Medica, Chinese Academy of Sciences ShanghaiChina
                [3 ]University of Chinese Academy of Sciences BeijingChina
                [4 ]deptThe National Center for Drug Screening Shanghai Institute of Materia Medica, Chinese Academy of Sciences ShanghaiChina
                [5 ]deptSchool of Life Science and Technology ShanghaiTech University ShanghaiChina
                [6 ]deptDepartment of Pharmacology and Toxicology, Medical College of Georgia Augusta University AugustaUnited States
                [7 ]deptDepartment of Chemistry and Chemical Biology Harvard University CambridgeUnited States
                [8 ]MRC Laboratory of Molecular Biology CambridgeUnited Kingdom
                [9 ]deptSchool of Pharmacy Fudan University ShanghaiChina
                DE Shaw Research United States
                Weill Cornell Medicine United States
                DE Shaw Research United States
                Author notes
                [†]

                These authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0001-8124-3079
                http://orcid.org/0000-0003-3028-3243
                https://orcid.org/0000-0002-4769-2265
                https://orcid.org/0000-0001-7279-2893
                https://orcid.org/0000-0001-7550-0921
                https://orcid.org/0000-0001-5609-434X
                Article
                50279
                10.7554/eLife.50279
                6954041
                31855179
                c9b39d0c-0a34-4b82-82cf-7e0e7f00e011
                © 2019, Zhou et al

                This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

                History
                : 17 July 2019
                : 19 December 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MC_U105185859
                Award Recipient :
                Funded by: Novo Nordisk-CAS Research;
                Award ID: NNCAS-2017-1-CC
                Award Recipient :
                Funded by: Young Talent Program of Shanghai;
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100012543, Shanghai Science and Technology Development Fund;
                Award ID: 16ZR1448500
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100012543, Shanghai Science and Technology Development Fund;
                Award ID: 16ZR1407100
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 21704064
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81573479
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81773792
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 31971178
                Award Recipient :
                Funded by: National Mega R&D Program for Drug Discovery;
                Award ID: 2018ZX09735-001
                Award Recipient :
                Funded by: National Key R&D Program of China;
                Award ID: 2016YFC0905900
                Award Recipient :
                Funded by: National Mega R&D Program for Drug Discovery;
                Award ID: 2018ZX09711002-002-005
                Award Recipient :
                Funded by: National Key R&D Program of China;
                Award ID: 2018YFA0507000
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81872915
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000057, National Institute of General Medical Sciences;
                Award ID: GM130142
                Award Recipient :
                The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
                Categories
                Research Article
                Computational and Systems Biology
                Structural Biology and Molecular Biophysics
                Custom metadata
                Contrary to previous findings, class A GPCRs share a common activation pathway that directly links ligand binding to G-protein activation, as revealed by novel quantitative analysis.

                Life sciences
                allostery,gpcr,activation mechanism,genetic diseases,signal transduction,drug discovery,human

                Comments

                Comment on this article